Key result
Corticosteroid therapy significantly decreased the proportion of CD14++CD16+ monocytes from 22.2% to 8.4% in patients with cardiac sarcoidosis, which correlated with reduced inflammatory activity.
Why the study?
Does corticosteroid therapy reduce circulating CD14++CD16+ monocytes and myocardial inflammatory activity on 18F-FDG PET in patients with cardiac sarcoidosis?
Observational (n=28)
No
Does corticosteroid therapy reduce circulating CD14++CD16+ monocytes and myocardial inflammatory activity on 18F-FDG PET in patients with cardiac sarcoidosis?
Circulating CD14++CD16+ monocytes decrease significantly following corticosteroid therapy in cardiac sarcoidosis, correlating with reduced myocardial inflammation on 18F-FDG PET, suggesting utility as a surrogate marker for treatment response.
Answers are grounded in this paper and cite their sources.
Monocyte reduction may indicate corticosteroid response in cardiac sarcoidosis; leaves open validation as surrogate marker in prospective studies.
BACKGROUND: We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET). METHODS AND RESULTS: We studied 28 patients with CS (8 men; mean age: 61±9 years) diagnosed according to consensus criteria. We divided the patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+); n=13) and new-onset CS (Rx(-); n=15), and analyzed 3 distinct monocyte subsets (CD14+CD16-, CD14++CD16+, and CD14+ -CD16+). Monocyte subsets were also analyzed in 10 Rx(-) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by 18F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14++CD16+ monocytes in Rx(+) patients (10.8 [0.2-23.5] %) was significantly lower than in Rx(-) patients (23.0 [11.5-38.4] %, P=0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14-0.62] to 0.17 [0.04-0.43] (P=0.017). The proportion of CD14++16+ monocytes showed a significant decrease from 22.2 [8.8-38.4] % to 8.4 [1.8-16.8] % (P=0.001). The decrease in the proportion of CD14++16+ monocytes significantly correlated with the decrease in the COV of the SUV (r=0.495, P=0.027). CONCLUSIONS: CD14++16+ monocytes are a possible surrogate marker of the therapeutic effect of corticosteroid therapy in CS.
No takes yet. Share an insight, caveat, or question.
Orii et al. (2015) conducted an observational in Cardiac sarcoidosis (n=28). Corticosteroid therapy vs. Baseline (before therapy) was evaluated on Proportion of CD14++CD16+ monocytes (p=0.001). Corticosteroid therapy significantly decreased the proportion of CD14++CD16+ monocytes from 22.2% to 8.4% in patients with cardiac sarcoidosis, which correlated with reduced inflammatory activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: